TPF Followed by Cetuximab and IMRT Plus Carbon Ion Boost for Locally Advanced Head and Neck Tumors

Inclusion Criteria: * Signed written informed consent, * Age of 18 to 70 years, * Life expectancy of at least 6 month, * Ability of subject to understand character and individual consequences of clinical trial, * Histologically confirmed locally advanced (stage III or IV), non-metastatic squamous cell carcinoma of oro-, hypopharynx and larynx (T2-4, any N, M0), * Oral cavity or oro- , hypopharynx or laynx as the primary tumor site, * At least one uni-measurable lesion according to the RECIST criteria, Karnofsky Performances Status \> 70%, * Adequate bone marrow function: neutrophils \> 1.5 x 109/L, platelets \> 100 x 109/L, hemoglobin \> 10.0 g/dL, * Adequate liver function: Bilirubin \< 1.5 mg/dL, SGOT, SGPT \< 3 x ULN, GGT \< 5 x ULN, * Adequate renal function: GFR\> 70 ml/min, * Negative serum/urine Beta-HCG test in women of childbearing potential, * Women of childbearing potential: willingness to use effective contraceptive method, defined as the concomitant use of either an intrauterine pessary (IUP) or contraceptive pill and in both cases, condoms for the treatment duration and 2 months thereafter. Women of non-childbearing potiential are those who are post-menopausal for at least 1 year or sterilized, * Men of procreative potential: willingness for effective prevention of procreation, defined as a use of condoms and a use of either an intrauterine pessary (IUP) or a contraceptive pill by his partner for the treatment duration and 2 months thereafter, * Subject's consent to collect blood and/or tumor tissue samples for proteomics and genomics. If a patient does not consent, no samples for proteomics and genomics will be taken. Nonetheles, he/she may be enroled in the study Exclusion Criteria: * Previous systemic chemotherapy, radiotherapy or surgery for carcinoma of the head, neck and larynx, * Nasopharyngeal Carcinoma, * Prior exposure to EGFR pathway targeting therapy, * Evidence of distant metastases. * Other serious illness or medical conditions: * Unstable cardiac disease despite treatment, congestive heart failure NYHA grade 3 and 4, * Significant neurologic or psychiatric disorders including dementia or seizures, * Active disseminated intravascular coagulation, * Other serious underlying medical conditions which in the opinion of investigator could impair the ability of the patient to participate in the study, * Symptomatic peripheral neuropathy Common Toxicity Criteria (CTC) grade 2 or higher, * ototoxicity CTC grade 2 or higher, except if due to trauma or mechanical impairment due to tumor mass, * Participation in other interventional trial within the last 30 days§§, * Surgery within the last 30 days, * Known allergic/hypersensitivity reaction to any drugs scheduled for the study treatment, * Women: pregnant or breast-feeding, * Known drug abuse, * Other previous malignancy within 5 years, with exception of a history of a previous, adequately treated, basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix, * Legal incapacity or limited legal capacity, * Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent.